Essential thrombocythemia (ET) is an acquired, Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) that is characterized by a sustained elevation in platelet count (greater than 450 G/l on two occasions). Parturients with ET are at risk of hemorrhagic and, more commonly, thromboembolic events. If anticoagulated, the timing of neuraxial block will need to occur within a safe window. Early delivery planning with a multidisciplinary care team is, therefore, prudent and may prevent the need for an alternative to neuraxial analgesia/anesthesia.
KeywordsEssential thrombocythemia Anticoagulation Neuraxial analgesia/anesthesia